

## ASX Release

24 November 2022

### Completion of Non-renounceable Entitlement Offer and Shortfall Notice

Melbourne, Australia 24 November 2022: Anatara Lifesciences Limited ('**Anatara**' or 'the **Company**') (ASX: ANR) advises that the Company's pro-rata non-renounceable entitlement offer announced on 21 October 2022 (**Entitlement Offer**), closed on 21 November 2022.

Under the Entitlement Offer, eligible shareholders in Australia and New Zealand were able to subscribe for Anatara shares at a price of \$0.035 each on the basis of 1 new share (**New Shares**) for every 3 shares held at the Record Date. Eligible shareholders that participated in the Entitlement Offer would receive 1 free attaching unquoted option (**New Option**) for every 2 New Shares subscribed for, exercisable at \$0.07 and expiring on 11 December 2025. Eligible shareholders were able to apply for New Shares and New Options in addition to their entitlement but may be scaled back at the discretion of the Board of the Company.

The results of the Entitlement Offer are as follows:

	Number of New Shares	Number of New Options	Amount
New Shares and New Options offered under the Entitlement Offer	23,785,207 (approx.)	11,892,604 (approx.)	\$832,482
New Shares and New Options subscribed for under the Entitlement Offer	14,991,156	7,495,595	\$524,691
Shortfall	8,794,051	4,397,026 (subject to rounding)	\$307,791

The 14,991,156 New Shares and 7,495,595 New Options subscribed for will be issued on 28 November 2022 and an Appendix 2A lodged with the ASX for their quotation.

In consultation with Taylor Collison, the Lead Manager to the Entitlement Offer, the Company will seek to place the shortfall within three months from the closing date of the Entitlement Offer on the terms detailed in the Prospectus.

Funds from the Entitlement Offer will be used to reach interim read-out in the form of a futility analysis on Stage 1 of the GaRP-IBS (Irritable Bowel Syndrome) trial involving 90 participants, with analysis due no later than Q2CY2023. Funds will also be used for future project acquisitions and to strengthen Anatara's balance sheet.

Anatara expresses its appreciation to participating shareholders for their ongoing support.

This announcement has been approved by the Board of Anatara Lifesciences Limited.

—ENDS—

Anatara Lifesciences Limited  
Registered Office  
Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia  
Administration and R&D  
Suite 101, 55 Flemington Rd, North Melbourne, VIC 3051, Australia  
Email [info@anatara.com](mailto:info@anatara.com) | Website [anataralifesciences.com](http://anataralifesciences.com)

**For more information please contact:**

<b>General inquiries</b>	
David Brookes Chair, Anantara Lifesciences Ltd +61 (0) 411 712 579 <a href="mailto:dbrookes@anantara.com">dbrookes@anantara.com</a>	Dirk van Dissel Candour Advisory – Investor Relations +61 (0) 408 326 367 <a href="mailto:dirk@candouradvisory.com.au">dirk@candouradvisory.com.au</a>

### **About Anantara Lifesciences Ltd**

Anantara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anantara is a life sciences company with expertise in developing products for animal and human health. Anantara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

#### **Disclaimer**

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anantara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

